Evidence map›Paper›PMID 38031804›Full record

Trial reportHaematologica2024

Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.

Matthew J Maurer, Carla Casulo, Melissa C Larson, Thomas M Habermann, Izidore S Lossos, Yucai Wang, Loretta J Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin and 13 more

Open access · goldAbstract readComparative StudyClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 1 country.

Matthew J MaurerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA, 55902; Division of Hematology, Mayo Clinic, Rochester, MN, USA, 55905. maurer.matthew@mayo.edu.
Carla CasuloDepartment of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA, 14642.
Melissa C LarsonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA, 55902.
Thomas M HabermannDivision of Hematology, Mayo Clinic, Rochester, MN, USA, 55905.
Izidore S LossosDepartment of Medicine, Comprehensive Sylvester Cancer Center, University of Miami, Miami, FL, USA, 33124.
Yucai WangDivision of Hematology, Mayo Clinic, Rochester, MN, USA, 55905.
Loretta J NastoupilUniversity of Texas, MD Anderson Cancer Center, Houston, TX, USA, 77030.
Christopher StrouseDepartment of Medicine, University of Iowa, Iowa City, IA, USA, 52242.
Dai ChiharaUniversity of Texas, MD Anderson Cancer Center, Houston, TX, USA, 77030.
Peter MartinDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA, 10075.
Jonathon B CohenDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA, 30322.
Brad S KahlDepartment of Medicine, Washington University in St Louis, St Louis, MO, USA, 63130.
W Richard BurackDepartment of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA, 14642.
Jean L KoffDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA, 30322.
Yong MunGenentech, Inc., South San Francisco, CA, USA, 94080.
Anthony MasaquelGenentech, Inc., South San Francisco, CA, USA, 94080.
Mei WuGenentech, Inc., South San Francisco, CA, USA, 94080.
Michael C WeiGenentech, Inc., South San Francisco, CA, USA, 94080.
Ashwini ShewadeGenentech, Inc., South San Francisco, CA, USA, 94080.
Jia LiGenentech, Inc., South San Francisco, CA, USA, 94080.
James R CerhanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA, 55902.
Brian K LinkDepartment of Medicine, University of Iowa, Iowa City, IA, USA, 52242.
Christopher R FlowersUniversity of Texas, MD Anderson Cancer Center, Houston, TX, USA, 77030.
The University of Texas MD Anderson Cancer Center · USEmory University · USMayo Clinic in Florida · USUniversity of Iowa · USUniversity of Rochester · USWinnMed · USCornell University · USMayo Clinic · USSylvester Comprehensive Cancer Center · USWashington University in St. Louis · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)U01CA195568 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, FLOWERS, CHRISTOPHER R · 2015 to 2025
$22.1M
NCI NIH HHS P30 CA086862NCI NIH HHS U01 CA195568
6 · The paper itself

Abstract

Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells. A recent pivotal phase I/II clinical trial (GO29781) demonstrated that mosunetuzumab induced an overall response rate (ORR) of 80%, complete response (CR) rate of 60%, and a median progression-free survival (PFS) of 17.9 months in patients with relapsed/refractory (R/R) follicular lymphoma (FL) following at least two prior lines of systemic therapy, including alkylator and anti-CD20 antibody-based therapy. Historical data from cohorts receiving therapy for R/R FL can provide some context for interpretation of single-arm trials. We compared the results from the mosunetuzumab trial to outcomes from a cohort of patients with R/R FL from the LEO Consortium for Real World Evidence (LEO CReWE). We applied clinical trial eligibility criteria to the LEO CReWE cohort and utilized matching- adjusted indirect comparison weighting to balance the clinical characteristics of the LEO CReWE cohort with those from the mosunetuzumab trial. ORR (73%, 95% CI: 65-80%) and CR rates (53%, 95% CI: 45-61%) observed in the weighted LEO CReWE cohort were lower than those reported on the mosunetuzumab trial (ORR=80%, 95% CI: 70-88%; CR=60%, 95% CI: 49-70%, respectively). PFS at 12 months was similar in the weighted LEO CReWE (60%, 95% CI: 51-69%) and the mosunetuzumab (58%, 95% CI: 47-68%) trial. Sensitivity analyses examining the impact of matching variables, selection of line of therapy, and application of eligibility criteria provide context for best practices in this setting.

Indexed as

Lymphoma, FollicularAdultAgedAged, 80 and overAntibodies, BispecificAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedRecurrenceTreatment OutcomeAntibodies, BispecificAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Identifiers

PMID38031804
PMCPMC11215382
OpenAlexW4389180535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.